Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Xuan Bamboo Biotech-B (02575) being included in the Hang Seng Composite Index [1] - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026, leading to adjustments in the eligible stocks for the Hong Kong Stock Connect [1] - According to a report by CICC, Xuan Bamboo Biotech is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing time [1] Group 2 - On December 7, 2025, the National Healthcare Security Administration announced the results of the adjustment to the National Medical Insurance Drug List, with Xuan Bamboo Biotech's self-developed Class 1 innovative drug, palbociclib tablets, successfully included in the list [1] - This inclusion provides new benefits for reimbursement to patients with advanced breast cancer [1]
轩竹生物-B获纳入恒生综合指数 有望成为港股通标的